Last Updated: August 9, 2026

Mechanism of Action: Non-Nucleoside Reverse Transcriptase Inhibitors


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Mechanism of Action: Non-Nucleoside Reverse Transcriptase Inhibitors

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Labs Ltd SYMFI efavirenz; lamivudine; tenofovir disoproxil fumarate TABLET;ORAL 022142-001 Mar 22, 2018 AB RX Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Somerset Theraps Llc RILPIVIRINE HYDROCHLORIDE rilpivirine hydrochloride TABLET;ORAL 218798-001 Jan 29, 2026 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Msd Merck Co PIFELTRO doravirine TABLET;ORAL 210806-001 Aug 30, 2018 RX Yes Yes 8,486,975 ⤷  Start Trial Y Y ⤷  Start Trial
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 AB RX Yes Yes 8,754,065*PED ⤷  Start Trial Y ⤷  Start Trial
Gilead Sciences Inc ODEFSEY emtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarate TABLET;ORAL 208351-001 Mar 1, 2016 AB RX Yes Yes 9,296,769*PED ⤷  Start Trial Y ⤷  Start Trial
Hetero Labs Ltd Iii NEVIRAPINE nevirapine TABLET;ORAL 078584-001 May 22, 2012 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links